 |
5 Diseases |  |
1 Trial |
|
1 Trial |  |
89 News |  |
| «12 |
- ||| licogliflozin (LIK066) / Novartis
Enrollment closed, Trial initiation date: A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults (clinicaltrials.gov) - Nov 9, 2017
P2, N=460, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Initiation date: Jan 2000 --> May 2017
- |||| licogliflozin (LIK066) / Novartis
Trial completion: Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066 (clinicaltrials.gov) - Oct 31, 2017
P2, N=54, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Initiation date: Jan 2000 --> May 2017 Recruiting --> Completed
- ||||| licogliflozin (LIK066) / Novartis
New P2 trial: A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity (clinicaltrials.gov) - Oct 25, 2017
P2, N=130, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| licogliflozin (LIK066) / Novartis
Enrollment open: Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients (clinicaltrials.gov) - Oct 23, 2017
P2, N=110, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- licogliflozin (LIK066) / Novartis
Trial primary completion date: Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. (clinicaltrials.gov) - Oct 18, 2017
P2, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2018 --> Nov 2017
- ||| licogliflozin (LIK066) / Novartis
Trial initiation date, Trial primary completion date: A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults (clinicaltrials.gov) - Oct 3, 2017
P2, N=432, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2018 --> Nov 2017 Initiation date: May 2017 --> Jan 2000 | Trial primary completion date: Aug 2018 --> Feb 2018
- | licogliflozin (LIK066) / Novartis
Enrollment open: Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066 (clinicaltrials.gov) - Aug 10, 2017
P2, N=48, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: May 2017 --> Jan 2000 | Trial primary completion date: Aug 2018 --> Feb 2018 Not yet recruiting --> Recruiting
- || licogliflozin (LIK066) / Novartis
Trial primary completion date: Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients (clinicaltrials.gov) - Jul 29, 2017
P2, N=110, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2019 --> Apr 2019
- | licogliflozin (LIK066) / Novartis
Enrollment open: Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - Jul 25, 2017
P2, N=24, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2019 --> Apr 2019 Not yet recruiting --> Recruiting
- |||| licogliflozin (LIK066) / Novartis
Clinical: A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure (clinicaltrials.gov) - Jul 21, 2017
P2, N=496, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| licogliflozin (LIK066) / Novartis
New P2 trial: Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients (clinicaltrials.gov) - Jul 2, 2017
P2, N=110, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | licogliflozin (LIK066) / Novartis
New P2 trial: Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066 (clinicaltrials.gov) - Jun 26, 2017
P2, N=48, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | licogliflozin (LIK066) / Novartis
Enrollment open: Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. (clinicaltrials.gov) - May 26, 2017
P2, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| licogliflozin (LIK066) / Novartis
Enrollment open: A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults (clinicaltrials.gov) - May 16, 2017
P2, N=432, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| licogliflozin (LIK066) / Novartis
Clinical: A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure (clinicaltrials.gov) - May 15, 2017
P2, N=496, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | licogliflozin (LIK066) / Novartis
New P2 trial: Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - May 15, 2017
P2, N=24, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | licogliflozin (LIK066) / Novartis
New P2 trial: Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function. (clinicaltrials.gov) - Apr 27, 2017
P2, N=50, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| licogliflozin (LIK066) / Novartis
New P2 trial: A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults (clinicaltrials.gov) - Apr 4, 2017
P2, N=432, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| licogliflozin (LIK066) / Novartis
Trial completion: Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index (clinicaltrials.gov) - Apr 13, 2016
P2, N=181, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| licogliflozin (LIK066) / Novartis
New P2 trial: Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index (clinicaltrials.gov) - Jun 12, 2015
P2, N=176, Recruiting, Sponsor: Novartis Pharmaceuticals
- licogliflozin (LIK066) / Novartis
Phase classification: Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Feb 6, 2015
P1/2, N=14, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Phase classification: P2 --> P1/2
- licogliflozin (LIK066) / Novartis
Trial withdrawal, Monotherapy: Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes (clinicaltrials.gov) - Apr 1, 2014
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Phase classification: P2 --> P1/2 Not yet recruiting --> Withdrawn
- licogliflozin (LIK066) / Novartis
Trial initiation date, Monotherapy: Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes (clinicaltrials.gov) - Apr 1, 2014
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Withdrawn Initiation date: Dec 2013 --> Nov 2015
- licogliflozin (LIK066) / Novartis
Enrollment change, Monotherapy: Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes (clinicaltrials.gov) - Apr 1, 2014
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Dec 2013 --> Nov 2015 N=491 --> 0
- | licogliflozin (LIK066) / Novartis
Trial completion: Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 5, 2014
P2, N=14, Completed, Sponsor: Novartis Pharmaceuticals
N=491 --> 0 Recruiting --> Completed
- | licogliflozin (LIK066) / Novartis
New P2 trial: Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 1, 2013
P2, N=14, Completed, Sponsor: Novartis Pharmaceuticals
- |||| licogliflozin (LIK066) / Novartis
Trial completion: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Jul 9, 2013
P1/2, N=138, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- licogliflozin (LIK066) / Novartis
New P2 trial, Monotherapy: Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes (clinicaltrials.gov) - Apr 2, 2013
P2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals